FY2029 EPS Estimates for PolyPid Decreased by HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – HC Wainwright lowered their FY2029 earnings estimates for PolyPid in a report issued on Wednesday, August 12th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.75 per share for the year, down from their previous estimate of $0.80. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $1.57 EPS.

Other research analysts also recently issued research reports about the stock. Craig Hallum set a $12.00 price objective on shares of PolyPid in a report on Wednesday, July 22nd. Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.33.

PolyPid Stock Performance

Shares of NASDAQ PYPD opened at $4.84 on Thursday. The company has a market cap of $92.35 million, a P/E ratio of -2.53 and a beta of 1.41. PolyPid has a 52-week low of $3.06 and a 52-week high of $5.73. The firm’s fifty day moving average is $4.74 and its two-hundred day moving average is $4.57.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03.

Institutional Investors Weigh In On PolyPid

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its position in PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of PolyPid in the 4th quarter worth about $44,000. Jane Street Group LLC bought a new stake in shares of PolyPid in the 4th quarter worth about $66,000. Renaissance Technologies LLC bought a new position in shares of PolyPid in the 1st quarter valued at about $81,000. Finally, XTX Topco Ltd lifted its holdings in shares of PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares during the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.